Michael Cookson to Chemotherapy, Adjuvant
This is a "connection" page, showing publications Michael Cookson has written about Chemotherapy, Adjuvant.
Connection Strength
0.815
-
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021 Jan; 205(1):22-29.
Score: 0.172
-
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021 Jan; 205(1):14-21.
Score: 0.172
-
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol. 2020 07; 38(7):639.e1-639.e9.
Score: 0.165
-
Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015 Jan; 67(1):165-170.
Score: 0.108
-
Beneficial impact of a clinical care pathway in patients with testicular cancer undergoing retroperitoneal lymph node dissection. J Urol. 2002 Jul; 168(1):87-92.
Score: 0.049
-
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol. 1997 Mar; 79(3):432-8.
Score: 0.034
-
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9.
Score: 0.028
-
Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology. 2014 Jan; 83(1):75-80.
Score: 0.027
-
Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol. 2014 Feb; 191(2):329-34.
Score: 0.026
-
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
Score: 0.017
-
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology. 1997 Mar; 49(3A Suppl):46-55.
Score: 0.008
-
Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology. 1997 Mar; 49(3A Suppl):95-101.
Score: 0.008